Cost analysis study of oral antihypertensive agents available in Indian market

Ashwini V. Karve, Kanchan B. Chattar

Abstract


Background: Hypertension is one of the major causes of morbidity, mortality and needs lifelong treatment. There is a wide range of variation in the prices of antihypertensive drugs marketed in India. Thus, a study was planned to find out price variations in the oral antihypertensive drugs available either singly or in combination and number of manufacturing companies for each, also to evaluate the difference in cost of different brands of same active drug by calculating percentage variation of cost.

Methods: Cost of a particular drug being manufactured by different companies, in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” July‑October 2013 and “Indian Drug Review” September 2013. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in price was calculated.

Results: Percentage price variation of the commonly used drugs found was amlodipine (5 mg): 1128.57%, atenolol (12.5 mg): 683.53%, enalapril (10 mg): 394.67%, telmisartan (20 mg): 288.33%. Among the combination therapy, amlodipine + atenolol (5 + 50 mg): 673.79%, amlodipine + losartan (5 + 50 mg): 284.61%, telmisartan + hydrochlorothiazide (40 + 12.5 mg): 293.85%, losartan + hydrochlorothiazide (50 + 12.5 mg): 384.62% variation.

Conclusion: The average percentage price variation of different brands of the same oral antihypertensive drug manufactured in India is very wide. The appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.


Keywords


Price variation, Anti hypertensive drugs, Brands

Full Text:

PDF

References


Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160 3.

Patel D, Thiyagu R, Surulivelrajan M, Patel H, Pandey S. Price variability among the oral antibiotics available in a South Indian Tertiary Care Hospital. J Clin Diagn Res. 2009;3(6):1871 5.

Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35 8.

Indrayan A. Epidemiology of hypertension. J Assoc Physicians India. 1994 Feb;42(2):175-6.

Mahal A, Karan A, Engelgau M. The Economic Implications of Noncommunicable Disease for India.Washington, DC: World Bank; 2010.

Jana S, Mondal P. Pharmacoeconomics: The need to sensitize undergraduate medical students. Indian Pharmacol 2005;37(5):277 8.

National List of Essential Medicines, 2011. Available from: http://www.mohfw.nic.in/WriteReadData/1892s/7364497513National%20Listof%20Essential%20Medicine, %202011. [Last accessed on 2013 Dec 10].

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K, editors. A Textbook of Clinical Pharmacy Practice. 1st Edition. Himayatnagar, Hyderabad: Orient Longman; 2004: 72 3.

World Health Organization. Essential drugs and medicines: Drug finance. Available from: http://www.whoindia.org/EN/Section2/Section/Section160_959.htm. [Last accessed on 2013 Dec 2].

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116 21.

Sarkar PK. A rational drug policy. Indian J Med Ethics. 2004;12;30 5.

Roy V, Rewari S. Ambiguous drug pricing: A physician’s dilemma. Indian J Pharmacol 1998;30(6):404 7.

Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics. 1992;2(6):449 55.

Berki SE, Richards JW, Weeks HA. The mysteries of prescription pricing in retail pharmacies. Med Care. 1977;15(3):241 50.

Rataboli PV, Dang A. Antimicrobial price variation: Conundrum of medical profession! J Postgrad Med. 2007;53(1):72 4.

Dawadi S, Rao BS, Khan GM. Pattern of antimicrobial prescription and its cost analysis in respiratory tract infection. Kathmandu Univ J Sci Eng Technol. 2005;1(1):1-9.